区域药交所,要取代省标!?

2018-03-11 遥望 赛柏蓝

对于药品集采中的种种问题,和游洪涛一样,全国政协委员屈谦也建议打破市场壁垒 建立全国性药品交易平台。

“我们企业招标,每个地方要专门派人,一个省至少一个人管招标,一个人租个房子搞,这个成本一个人十几万,二十万,30个省就是几百万。”重庆市人大代表、重庆某制药股份有限公司董事长游洪涛在2018第十届医药界人大代表政协委员座谈会上说到。对此,相信不少企业都有同感。

对于药品集采中的种种问题,和游洪涛一样,全国政协委员屈谦也建议打破市场壁垒 建立全国性药品交易平台。

国务院医改办相关负责人也表示,将广泛听取相关部委、行业协会和企业、医院代表的意见,整顿省级药品集中采购平台职能,规范其向第三方平台机制转型。

▍全国性药交平台的优势

游洪涛在座谈会上说到,评价好,比较透明,交易成本降低是全国性药品交易平台的三个优势。企业在网上投标,不需要派人专门去,有一个端口,直接网上操作。

根据重庆药交所的运营经验来看,大数据实施情况非常好,而且技术成熟。医院认同,药企满意,而药品价格也得到了有效的降低。

游洪涛建议,下一步,在药品招标采购的过程中,在全国建立几个区域性的药品交易所,避免产生腐败、地方保护,降低企业的负担。有利于建立全国统一的市场,打破地方保护。

▍药品招采的问题

全国政协委员屈谦对媒体表示,目前,药品采购上面临一些问题:

如,行政地域化较突出,造成全国市场分割,难以形成统一、开放、公平的市场秩序;

地方保护、市场壁垒等多种因素的存在;

企业面对各省的招标组织,应对不同的招标政策,营销成本畸高,恶性竞争严重;

各地重复建设招标平台造成资源浪费。

对此,他表示逐步建立全国统一或按大区划分的第三方医药交易公共服务平台时机已经成熟。

目前的跨区域采购平台有京津冀医用耗材联合采购平台,跨区域采购联盟有三明联盟、沪苏浙皖闽四省一市、西部高值耗材采购联盟,重庆药交所模式在推广的过程中,也将面临一定的竞争。不过,对于药企来说,他们又将增加一个强有力的议价采购单元。

附:全国药交平台的7个作用

一是符合党中央、国务院关于建立统一市场体系、简政放权、推进价格改革等精神,为推进药品价格改革提供有效的载体,发挥市场在药品资源配置、价格调节中的决定性作用。

二是维护医药市场的完整性和统一性,打破地方保护和市场壁垒,形成公平、统一、规范、有序的市场秩序。

三是发现药品市场合理价格。全国统一平台交易,增大价格谈判砝码(尤其是外资药品价格谈判的主动权),有助于发现市场价格,逐步从国内的价格发现中心升级为全球药品定价中心。

四是规范药品流通秩序,保障药品质量和供应。通过平台交易和智能追溯,全面支撑从生产到流通到医疗机构各开一次发票的“两票制”。同时,平台整合的“产供销用存”等大数据可以为政府决策和监督提供参考和支撑,提高医药流通监管效率,降低监管成本,保障药品供应和安全。

五是促进公平有序竞争,促进医药产业健康发展。通过互联网技术显著降低药品生产企业的运营成本,避免一个企业应对30个省级采购中心、几百个地市级谈判机构,减轻医药企业制度性交易成本,同时在统一开放的市场环境下,医药企业公平竞争,通过市场调节手段实现优胜劣汰、优化重组,推动医药产业供给侧改革,促进医药产业规模化、集约化发展。

六是助力深化医改,推动实施健康中国战略。平台通过全流程交易实现商流、物流、信息流、资金流、数据流“五流合一”,确保信息数据的统一性、公益性、安全性、准确性和保密性,通过大数据整合、共享共用,推动三医联动改革,服务健康中国战略。

七是通过实施统一的制度规则、共享的信息系统、规范透明的运行机制,为交易主体、社会公众、行政监管部门等提供综合服务,减少药械购销领域的不正之风和暗箱操作。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=307632, encodeId=c2cc30e632e9, content=好好好学习天天向上好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Fri Apr 20 18:10:30 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299604, encodeId=b0b429960467, content=好好好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Sun Mar 25 19:43:07 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295425, encodeId=b5772954256a, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Mon Mar 12 07:26:49 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295114, encodeId=e50529511433, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Mar 11 07:45:12 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295069, encodeId=d49c29506953, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Mar 11 06:45:50 CST 2018, time=2018-03-11, status=1, ipAttribution=)]
    2018-04-20 zwjnj2

    好好好学习天天向上好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=307632, encodeId=c2cc30e632e9, content=好好好学习天天向上好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Fri Apr 20 18:10:30 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299604, encodeId=b0b429960467, content=好好好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Sun Mar 25 19:43:07 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295425, encodeId=b5772954256a, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Mon Mar 12 07:26:49 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295114, encodeId=e50529511433, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Mar 11 07:45:12 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295069, encodeId=d49c29506953, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Mar 11 06:45:50 CST 2018, time=2018-03-11, status=1, ipAttribution=)]
    2018-03-25 zwjnj2

    好好好好学习天天向上

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=307632, encodeId=c2cc30e632e9, content=好好好学习天天向上好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Fri Apr 20 18:10:30 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299604, encodeId=b0b429960467, content=好好好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Sun Mar 25 19:43:07 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295425, encodeId=b5772954256a, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Mon Mar 12 07:26:49 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295114, encodeId=e50529511433, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Mar 11 07:45:12 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295069, encodeId=d49c29506953, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Mar 11 06:45:50 CST 2018, time=2018-03-11, status=1, ipAttribution=)]
    2018-03-12 wzb521zf

    一起学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=307632, encodeId=c2cc30e632e9, content=好好好学习天天向上好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Fri Apr 20 18:10:30 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299604, encodeId=b0b429960467, content=好好好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Sun Mar 25 19:43:07 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295425, encodeId=b5772954256a, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Mon Mar 12 07:26:49 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295114, encodeId=e50529511433, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Mar 11 07:45:12 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295069, encodeId=d49c29506953, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Mar 11 06:45:50 CST 2018, time=2018-03-11, status=1, ipAttribution=)]
    2018-03-11 1dd8c52fm63(暂无匿称)

    了解了解.继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=307632, encodeId=c2cc30e632e9, content=好好好学习天天向上好, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Fri Apr 20 18:10:30 CST 2018, time=2018-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299604, encodeId=b0b429960467, content=好好好好学习天天向上, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Sun Mar 25 19:43:07 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295425, encodeId=b5772954256a, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Mon Mar 12 07:26:49 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295114, encodeId=e50529511433, content=了解了解.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Sun Mar 11 07:45:12 CST 2018, time=2018-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=295069, encodeId=d49c29506953, content=好好好好好好好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sun Mar 11 06:45:50 CST 2018, time=2018-03-11, status=1, ipAttribution=)]
    2018-03-11 yjs木玉

    好好好好好好好好

    0

相关资讯

内蒙古推“互联网+”药品配送

近日,内蒙古自治区制定出台《关于进一步改革完善药品生产流通使用政策的实施意见》,提出支持药品流通企业与互联网企业加强合作,取消“互联网药品交易服务企业审批”行政许可事项。